Takeda Leans on a Little Guy, Ovid Therapeutics, to Go the Distance With an Epilepsy Drug

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

In Support of FDA’s Authority to Regulate Medicines
A Moment of Truth
Barring Foreign Talent Is An Assault on Biotech Innovation
Ovid Therapeutics Finds European Partner to Advance Treatment for Rare Neurological Disease